Updates in Targeted Therapies for B-Cell Malignancies

EP. 1: Ibrutinib's Role as Frontline Therapy in CLL

July 26th 2019

EP. 2: Stratifying Patients With CLL to Frontline Therapy

July 26th 2019

EP. 3: Frontline Therapy in CLL: Combination Strategies and MRD

July 26th 2019

EP. 4: Venetoclax + Obinutuzumab: Impact on CLL Management

July 26th 2019

EP. 5: Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

July 26th 2019

EP. 6: CLL: Practical Advice on Selecting and Managing Therapy

July 26th 2019

EP. 7: Mantle Cell Lymphoma: An Overview on Frontline Therapy

July 26th 2019

EP. 8: Selection of a BTK Inhibitor in Relapsed/Refractory MCL

July 26th 2019

EP. 9: R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

July 26th 2019

EP. 10: Practical Advice on the Future Management of MCL

July 26th 2019

EP. 11: Waldenstrom Macroglobulinemia: Indications for Treatment

July 26th 2019

EP. 12: BTK Inhibition's Role in Waldenstrom Macroglobulinemia

July 26th 2019

EP. 13: Waldenstrom Macroglobulinemia: Non-BTK Novel Strategies

July 26th 2019

EP. 14: Potential for CAR T-Cell Therapy in B-Cell Lymphomas

July 26th 2019

EP. 15: B-Cell Lymphomas: Practical Advice on CAR T-Cell Therapy

July 26th 2019